Innovate UK Announces £6.9 Million Funding for Neoplasm Biotechnology to Develop Novel Cancer Treatment
Investment to Accelerate Clinical Trials of Promising Antibody Therapy
Innovate UK, the UK's innovation agency, has awarded £6.9 million in funding to Neoplasm Biotechnology, a leading biotechnology company, to develop a novel cancer treatment. The funding will support clinical trials of the company's investigational antibody therapy, which has shown promising results in early-stage studies.
The Antibody Therapy
Neoplasm's antibody therapy targets a specific protein expressed on cancer cells. The antibody binds to this protein, blocking its activity and triggering the immune system to attack the cancer cells. The therapy has shown promising efficacy against a range of cancer types, including breast, lung, and ovarian cancer.
Clinical Trials
The funding from Innovate UK will enable Neoplasm to conduct a Phase II clinical trial of its antibody therapy in patients with advanced cancer. The trial will evaluate the safety and efficacy of the therapy and determine its potential for further development. The company plans to initiate the trial in early 2023 and expects to enroll over 200 patients.
Impact on Cancer Treatment
If successful, Neoplasm's antibody therapy could represent a significant advance in cancer treatment. The therapy has the potential to improve outcomes for patients with advanced cancer, who currently have limited treatment options. The funding from Innovate UK will accelerate the development of this promising therapy and bring it closer to patients who need it most.
Comments